Senior Scientist, Advanced Drug Delivery

At AstraZeneca, we turn ideas into life changing medicines and strive to continuously meet the unmet needs of patients worldwide. Working here means being entrepreneurial, thinking big, and working together to make the impossible a reality. If you are swift to action, confident to lead, willing to collaborate, and curious about what science can do, then you're our kind of person.

Pharmaceutical Sciences at AstraZeneca delivers the therapies of the future through scientific leadership in drug delivery, design of synthetic routes, and manufacturing of Active Pharmaceutical Ingredients (API) and drug products. Our portfolio of projects spans traditional small molecules, peptides, oligonucleotides to RNA based therapeutics across AstraZeneca's therapy areas. Advanced Drug Delivery (ADD) resides within Pharmaceutical Sciences with a mission to provide novel products to AstraZeneca's clinical pipeline.

We are now recruiting a hardworking and motivated Senior Scientist to join our New Modality CMC Analytics team within the Advanced Drug Delivery (ADD) function in Gothenburg, Sweden.



What you will do

As a Senior Scientist working in the clinical development phase within ADD you will be responsible for drug projects from an analytical perspective, from candidate drug nomination over Phase II clinical trials. You will focus on advanced analytical characterization of biomolecules, primarily nucleotide-based molecules such as oligonucleotides or RNA, but also other molecules as peptides and complex drug delivery systems. The role covers development and validation of analytical methods, stability studies, release analysis, authoring regulatory submissions as well as exploratory science work. Part of the work is performed according to Good Manufacturing Practice (GMP). You will work as a member of cross-functional pharmaceutical project teams and in close collaboration with other analysts, formulators, chemists and biologists at AstraZeneca in Sweden, UK and US.



Essential for the role

* MSc degree in a relevant scientific field (e.g. Analytical Chemistry, Biochemistry or Biotechnology)
* In-depth knowledge of analytical methodologies for nucleotide/peptide/biomolecule characterization, such as chromatography, mass spectrometry and other biophysical/chemical characterization techniques
* Experience of analytical work with biomolecules in pharmaceutical development
* Experience in authoring /reviewing relevant sections of regulatory files
* Thorough understanding of principles and applications of GMP
* Ability to communicate in English both orally and in writing



Desirable for the role

* Ph.D degree or 5+ years of industrial experience of analytical work with nucleotides/RNA/biomolecules in clinical drug development phase
* Expertise in analysis of nucleotide-based therapeutics for parenteral and oral administration routes
* Experience of different formulation/delivery systems that may require different sample preparation techniques
* Qualified to execute analytical work according to GMP
* An interest in exploratory analytical work related to complex molecules, delivery systems and new technologies with aim to publish and present scientific results and conclusions



At AstraZeneca when we see an opportunity for change, we seize it and make it happen, because any opportunity no matter how small, can be the start of something big. Delivering life-changing medicines is about being entrepreneurial - finding those moments and recognizing their potential. Join us on our journey of building a new kind of organisation to reset expectations of what a bio-pharmaceutical company can be. This means we're opening new ways to work, pioneering cutting edge methods and bringing unexpected teams together. Interested? Come and join our journey.

Are you already imagining yourself joining our team in Gothenburg? Good, because we can't wait to hear from you!

For more information please contact Gunilla Nilsson, Team Leader, +46 725821648, gunilla.a.nilsson@astrazeneca.com

Welcome with your application no later than October 25th, 2020.